Axsome Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 976.41, 1573.27, 2326.45, 3011.37, 3664.89 ], "ebit_estimate": [ -110.67, 305.96, 944.03, 1544.5, 2083.07 ], "ebitda_estimate": [ -36.33, 354.28, 714.54, 1550.1, 1629.95 ], "net_income_estimate": [ -90.71, 334.36, 839.02, 1316.64, 1719.34 ], "per_share_eps_estimate": [ -1.78, 6.32, 14.61, 23.45, 30.8 ], "eps_nri_estimate": [ -1.74, 6.39, 14.95, 23.28, 29.94 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 2.54, 12.14, 20.64, 55.39, 88.93 ], "pretax_income_estimate": [ -104.69, 328.42, 875.56, 1590.23, 2161.54 ], "operating_cash_flow_per_share_estimate": [ 1.61, 8.46, 15.83, 26.36, 33.49 ], "roa_estimate": [ -12.9, 31, 43.7, 41.5, 34.7 ], "roe_estimate": [ -49.07, 93.58, 69.14, 56.1, 42.2 ], "gross_margin_estimate": [ 92.68, 92.53, 92.73, 92.77, 92.59 ], "operating_cash_flow_estimate": [ 82.17, 433.3, 810.46, 1349.58, 1714.62 ], "pettm_estimate": [ 0, 36.98, 16, 9.97, 7.59 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "54.59", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 54.59, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 145.78, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.36, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 220.68, 262.02, 309.84, 307.03, 356.66, 403.74, 456.08, 367.05 ], "ebit_estimate": [ -42.59, -10.91, 23.91, 28.01, 54.52, 81.93, 112.14, 153.21 ], "ebitda_estimate": [ -27.3, 6.45, 44.82, 78.27, 100.99, 118.07, 145.86, 153.21 ], "net_income_estimate": [ -43.88, -10.67, 18.8, 24.14, 46.88, 70.4, 96.72, 145.64 ], "per_share_eps_estimate": [ -0.84, -0.29, 0.58, 0.52, 1.06, 1.53, 2.1, 2.42 ], "eps_nri_estimate": [ -0.84, -0.29, 0.35, 0.45, 1.06, 1.53, 2.06, 2.42 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 1.2, 1.9, 3.96, null, null, null, null, null ], "pretax_income_estimate": [ -43.21, -11, 22.67, 26.36, 52.73, 80.26, 110.62, 153.58 ], "operating_cash_flow_per_share_estimate": [ 4.18, 8.53, 13.6, 1.42, 1.83, 2.12, 2.6, 2.62 ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 92.83, 92.84, 92.69, 91.9, 92.4, 91.95, 91.95, null ], "operating_cash_flow_estimate": [ 213.75, 436.46, 696.29, 72.7, 93.69, 108.54, 133.12, 134.14 ], "pettm_estimate": [ 0, 124.49, 63.24, 44.8, 32.85, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "54.59", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 54.59, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 145.78, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 0.36, "future_operating_cash_flow_per_share_estimate_growth": null }